JP2017512759A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017512759A5 JP2017512759A5 JP2016554855A JP2016554855A JP2017512759A5 JP 2017512759 A5 JP2017512759 A5 JP 2017512759A5 JP 2016554855 A JP2016554855 A JP 2016554855A JP 2016554855 A JP2016554855 A JP 2016554855A JP 2017512759 A5 JP2017512759 A5 JP 2017512759A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- amino acid
- homologous
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 28
- 239000000427 antigen Substances 0.000 claims 23
- 102000036639 antigens Human genes 0.000 claims 23
- 108091007433 antigens Proteins 0.000 claims 23
- 210000004408 hybridoma Anatomy 0.000 claims 11
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- -1 Globo H Proteins 0.000 claims 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims 1
- 230000005907 cancer growth Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461977824P | 2014-04-10 | 2014-04-10 | |
| US61/977,824 | 2014-04-10 | ||
| US201462057381P | 2014-09-30 | 2014-09-30 | |
| US62/057,381 | 2014-09-30 | ||
| PCT/US2015/025305 WO2015157629A2 (en) | 2014-04-10 | 2015-04-10 | Antibodies, pharmaceutical compositions and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017512759A JP2017512759A (ja) | 2017-05-25 |
| JP2017512759A5 true JP2017512759A5 (Direct) | 2019-06-27 |
Family
ID=54288553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016554855A Pending JP2017512759A (ja) | 2014-04-10 | 2015-04-10 | 抗体、前記抗体を産生するハイブリドーマ、前記抗体を含む薬学的組成物及びその用途 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9902779B2 (Direct) |
| EP (2) | EP3129048B1 (Direct) |
| JP (1) | JP2017512759A (Direct) |
| KR (1) | KR101966408B1 (Direct) |
| CN (2) | CN112390887B (Direct) |
| AU (2) | AU2015243246B2 (Direct) |
| BR (1) | BR112016020009A2 (Direct) |
| CA (2) | CA3104268A1 (Direct) |
| CL (1) | CL2016002569A1 (Direct) |
| ES (1) | ES2772817T3 (Direct) |
| IL (2) | IL246837B (Direct) |
| PH (1) | PH12016501976A1 (Direct) |
| RU (1) | RU2016138744A (Direct) |
| SG (1) | SG11201607258SA (Direct) |
| TW (3) | TWI697503B (Direct) |
| WO (1) | WO2015157629A2 (Direct) |
| ZA (1) | ZA201605175B (Direct) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014391422A1 (en) | 2013-09-17 | 2015-12-17 | Obi Pharma, Inc. | Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment |
| US9828436B2 (en) | 2014-03-19 | 2017-11-28 | Mackay Medical Foundation The Presbyterian Church In Taiwan Mackay Memorial Hospital | Antibodies against immunogenic glycopeptides, compositions comprising the same and use thereof |
| SG11201607258SA (en) | 2014-04-10 | 2016-10-28 | Obi Pharma Inc | Antibodies, pharmaceutical compositions and uses thereof |
| KR20180050339A (ko) | 2015-09-04 | 2018-05-14 | 오비아이 파머 인코퍼레이티드 | 글리칸 어레이 및 사용 방법 |
| CA3000531A1 (en) | 2015-10-07 | 2017-04-13 | Obi Pharma, Inc. | Novel carbohydrate antibodies, pharmaceutical compositions and uses thereof |
| US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| KR20180121786A (ko) | 2016-03-29 | 2018-11-08 | 오비아이 파머 인코퍼레이티드 | 항체, 제약 조성물 및 방법 |
| SG11201809024UA (en) | 2016-04-22 | 2018-11-29 | Obi Pharma Inc | Cancer immunotherapy by immune activation or immune modulation via globo series antigens |
| GB201612317D0 (en) * | 2016-07-15 | 2016-08-31 | Philogen Spa | Antibody compositions |
| TWI752988B (zh) | 2016-07-27 | 2022-01-21 | 台灣浩鼎生技股份有限公司 | 免疫性/治療性聚醣組合物及其用途 |
| EP3491026A4 (en) | 2016-07-29 | 2020-07-29 | OBI Pharma, Inc. | HUMAN ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND PROCESSES |
| CN110290800A (zh) * | 2016-11-21 | 2019-09-27 | 台湾浩鼎生技股份有限公司 | 缀合生物分子、医药组合物及方法 |
| CA3064443A1 (en) * | 2017-05-24 | 2018-11-29 | Development Center For Biotechnology | Humanized antibodies against globo h and uses thereof in cancer treatments |
| CN112566642B (zh) * | 2018-03-14 | 2025-01-17 | 纪念斯隆凯特琳癌症中心 | 抗聚唾液酸抗体及其用途 |
| JP2021525756A (ja) * | 2018-06-01 | 2021-09-27 | オービーアイ ファーマ，インコーポレイテッド | 抗グロボｈ又は抗ｓｓｅａ−４抗体を、抗ネガティブ免疫チェックポイント抗体と共に使用することによる組合せ療法 |
| TW202504930A (zh) | 2018-06-27 | 2025-02-01 | 台灣浩鼎生技股份有限公司 | 用於糖蛋白工程的糖苷合成酶變體及其使用方法 |
| WO2020198699A2 (en) * | 2019-03-28 | 2020-10-01 | Obi Pharma, Inc. | Companion diagnostic assay for globo-h related cancer therapy |
| US20240066125A1 (en) * | 2021-02-09 | 2024-02-29 | Obi Pharma, Inc. | Globo series antigens-binding chimeric antigen receptors and uses thereof |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| EP0247091B1 (en) | 1985-11-01 | 1993-09-29 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| CA2119930C (en) | 1991-09-23 | 2002-10-01 | Hendricus R. J. M. Hoogenboom | Production of chimeric antibodies - a combinatorial approach |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| AUPO517897A0 (en) | 1997-02-19 | 1997-04-11 | Csl Limited | Chelating immunostimulating complexes |
| AUPP807399A0 (en) | 1999-01-08 | 1999-02-04 | Csl Limited | Improved immunogenic lhrh composition and methods relating thereto |
| DE60044236D1 (de) | 1999-02-17 | 2010-06-02 | Csl Ltd | Immunogene komplexe und methoden in bezug auf diese |
| US20040038339A1 (en) | 2000-03-24 | 2004-02-26 | Peter Kufer | Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| CU23007A1 (es) * | 2001-04-06 | 2004-12-17 | Ct De Inmunologia Molecular Ct De Inmunologia Mole | Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos |
| DE60124912T2 (de) * | 2001-09-14 | 2007-06-14 | Affimed Therapeutics Ag | Multimerische, einzelkettige, Tandem-Fv-Antikörper |
| BR0107262B1 (pt) | 2001-12-17 | 2014-04-22 | Da Fonseca Clovis Orlando Pereira | Composição farmacêutica inalatória |
| US20040126829A1 (en) | 2001-12-18 | 2004-07-01 | Hildebrand William H. | Anti-HLA assay and methods |
| ES2333952T3 (es) * | 2002-04-30 | 2010-03-03 | Kyowa Hakko Kirin Co., Ltd. | Anticuerpo para el factor de crecimiento humano de tipo insulinico. |
| AU2003232456B2 (en) * | 2002-05-30 | 2009-06-04 | Macrogenics, Inc. | CD16A binding proteins and use for the treatment of immune disorders |
| AT413486B (de) * | 2002-07-03 | 2006-03-15 | Igeneon Krebs Immuntherapie | Verwendung eines antikörpers gerichtet gegen lewis-antigene |
| ES2643760T3 (es) | 2004-02-06 | 2017-11-24 | University Of Massachusetts | Anticuerpos contra toxinas de Clostridium difficile y usos de los mismos |
| AU2005259221B2 (en) * | 2004-07-01 | 2011-02-10 | Innate Pharma | Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use |
| AU2005333126A1 (en) | 2004-07-18 | 2006-12-21 | Csl Limited | Methods and compositions for inducing innate immune responses |
| KR20100018029A (ko) | 2004-07-18 | 2010-02-16 | 씨에스엘 리미티드 | 면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기 위한 올리고뉴클레오티드 제제 |
| NZ556029A (en) * | 2004-12-21 | 2010-04-30 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
| PT1871805T (pt) * | 2005-02-07 | 2019-12-02 | Roche Glycart Ag | Moléculas de ligação a antigénios que se ligam ao rfce, vetores que as codificam e as suas utilizações |
| PT2343320T (pt) * | 2005-03-25 | 2018-01-23 | Gitr Inc | Anticorpos anti-gitr e as suas utilizações |
| CL2007002668A1 (es) * | 2006-09-20 | 2008-05-09 | Amgen Inc | Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2. |
| EP1920782A1 (en) | 2006-11-10 | 2008-05-14 | Glycotope Gmbh | Carboyhdrate specific cellular immunity inducing microorganisms and fractions thereof |
| US20100145032A1 (en) * | 2007-01-18 | 2010-06-10 | Suomen Punainen Risti, Veripalelu | Novel carbohydrate profile compositions from human cells and methods for analysis and modification thereof |
| WO2010005735A2 (en) * | 2008-06-16 | 2010-01-14 | Academia Sinica | Compositions for inducing immune responses specific to globo h and ssea3 and uses thereof in cancer treatment |
| CN102066940B (zh) | 2008-06-16 | 2015-05-13 | 中央研究院 | 根据对抗Globo H及其片段的抗体量的癌症诊断 |
| TWI392502B (zh) * | 2009-06-16 | 2013-04-11 | Academia Sinica | 聚己醣抗原及含新穎醣脂質佐劑之相關抗癌疫苗 |
| JP5769316B2 (ja) * | 2009-08-06 | 2015-08-26 | イムナス・ファーマ株式会社 | Ａβオリゴマーに特異的に結合する抗体およびその利用 |
| WO2011136911A2 (en) | 2010-04-09 | 2011-11-03 | Aveo Pharmaceuticals, Inc. | Anti-erbb3 antibodies |
| DK2588616T3 (en) * | 2010-07-01 | 2019-03-11 | Dsm Ip Assets Bv | PROCEDURE FOR MAKING A RELATIONSHIP OF INTEREST |
| SG187867A1 (en) * | 2010-08-16 | 2013-03-28 | Amgen Inc | Antibodies that bind myostatin, compositions and methods |
| TW201307388A (zh) * | 2010-12-21 | 2013-02-16 | Abbott Lab | Ｉｌ－１結合蛋白 |
| EP2497782A1 (en) * | 2011-03-08 | 2012-09-12 | Alzinova AB | Anti oligomer antibodies and uses thereof |
| US9828635B2 (en) | 2011-10-06 | 2017-11-28 | Aveo Pharmaceuticals, Inc. | Predicting tumor response to anti-ERBB3 antibodies |
| EP3093294A1 (en) | 2012-02-24 | 2016-11-16 | Stemcentrx, Inc. | Dll3 modulators and methods of use |
| AU2015206370A1 (en) | 2014-01-16 | 2016-07-07 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
| US9828436B2 (en) * | 2014-03-19 | 2017-11-28 | Mackay Medical Foundation The Presbyterian Church In Taiwan Mackay Memorial Hospital | Antibodies against immunogenic glycopeptides, compositions comprising the same and use thereof |
| SG11201607258SA (en) | 2014-04-10 | 2016-10-28 | Obi Pharma Inc | Antibodies, pharmaceutical compositions and uses thereof |
-
2015
- 2015-04-10 SG SG11201607258SA patent/SG11201607258SA/en unknown
- 2015-04-10 TW TW106128654A patent/TWI697503B/zh active
- 2015-04-10 AU AU2015243246A patent/AU2015243246B2/en not_active Ceased
- 2015-04-10 EP EP15777370.6A patent/EP3129048B1/en active Active
- 2015-04-10 CN CN202011258954.4A patent/CN112390887B/zh active Active
- 2015-04-10 JP JP2016554855A patent/JP2017512759A/ja active Pending
- 2015-04-10 EP EP20151337.1A patent/EP3662928A1/en not_active Withdrawn
- 2015-04-10 KR KR1020167024072A patent/KR101966408B1/ko not_active Expired - Fee Related
- 2015-04-10 TW TW104111557A patent/TWI609886B/zh active
- 2015-04-10 ES ES15777370T patent/ES2772817T3/es active Active
- 2015-04-10 TW TW106128651A patent/TWI695013B/zh active
- 2015-04-10 WO PCT/US2015/025305 patent/WO2015157629A2/en not_active Ceased
- 2015-04-10 CN CN201580011286.6A patent/CN106456727B/zh active Active
- 2015-04-10 RU RU2016138744A patent/RU2016138744A/ru not_active Application Discontinuation
- 2015-04-10 BR BR112016020009A patent/BR112016020009A2/pt not_active IP Right Cessation
- 2015-04-10 CA CA3104268A patent/CA3104268A1/en not_active Abandoned
- 2015-04-10 CA CA2941029A patent/CA2941029C/en active Active
- 2015-04-10 US US15/303,132 patent/US9902779B2/en active Active
-
2016
- 2016-07-19 IL IL246837A patent/IL246837B/en active IP Right Grant
- 2016-07-25 ZA ZA2016/05175A patent/ZA201605175B/en unknown
- 2016-10-04 PH PH12016501976A patent/PH12016501976A1/en unknown
- 2016-10-07 CL CL2016002569A patent/CL2016002569A1/es unknown
-
2017
- 2017-11-28 US US15/824,733 patent/US10815307B2/en active Active
-
2018
- 2018-10-26 AU AU2018253589A patent/AU2018253589B2/en not_active Ceased
-
2020
- 2020-08-13 IL IL276695A patent/IL276695B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017512759A5 (Direct) | ||
| IL276695A (en) | Antibodies, pharmaceutical compositions and uses thereof | |
| IL276830B2 (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| JP2023002562A5 (Direct) | ||
| RU2018119165A (ru) | Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение | |
| JP2020528750A5 (Direct) | ||
| RU2018145852A (ru) | Антитело против lag-3, его антигенсвязывающий фрагмент и их фармацевтическое применение | |
| JP2017149720A5 (Direct) | ||
| NZ597067A (en) | Monoclonal antibodies expressed by ATCC PTA-4621 for the treatment of cancer | |
| JP2015535828A5 (Direct) | ||
| RU2018124602A (ru) | Новые анти-pd-l1 антитела | |
| CN112513094A (zh) | 结合人her2的抗体、其制备方法和用途 | |
| CN111278861A (zh) | Pd-l1抗体、其抗原结合片段及医药用途 | |
| JP2016526904A5 (Direct) | ||
| JP2018504105A5 (Direct) | ||
| NZ609619A (en) | Novel egfr-binding molecules and immunoconjugates thereof | |
| HRP20151019T1 (hr) | PROTUTIJELA PROTIV c-MET | |
| RU2014122990A (ru) | Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas | |
| JP2013542194A5 (Direct) | ||
| RU2014103784A (ru) | Антитело, блокирующее agr2, и его применение | |
| JP2015506912A5 (Direct) | ||
| RU2012103212A (ru) | Tlr3 связывающие агенты | |
| RU2016137110A (ru) | Антитела к компоненту комплемента с5 | |
| JP2020522280A5 (Direct) | ||
| JP2021500916A5 (Direct) |